ESMO/X
Oct 14, 2024, 12:36
Updated data of KEYNOTE-716 and CheckMate 76K studies at ESMO24
The European Society for Medical Oncology (ESMO) shared a post on X:
“At ESMO24, updated data of KEYNOTE-716 and CheckMate 76K studies confirm the key role of anti-programmed cell death protein 1 (PD-1)-based immunotherapy in the adjuvant setting for patients with melanoma.”
More posts featuring ESMO.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 11:49
Nov 14, 2024, 11:46
Nov 14, 2024, 11:38
Nov 14, 2024, 11:30
Nov 14, 2024, 09:31
Nov 14, 2024, 09:26
Nov 14, 2024, 09:21
Nov 14, 2024, 09:15